<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190717044248N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-06-29</date_registration>
      <primary_sponsor>Rafsanjan University of Medical Sciences</primary_sponsor>
      <public_title>The effect of different doses of castor oil capsule (Gelax) on Bishop's score and some delivery outcomes</public_title>
      <acronym></acronym>
      <scientific_title>A comparative study on the effect of various doses of castor oil capsule (Gelax) on bishap score and some prenatal outcomes  in nulliparous women refer to Niknafs Rafsanjan maternity hospital in</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-01-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/44109</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple random sampling; Random numbers table
First, four centers from eight comprehensive health-care services centers in Rafsanjan will be selected as research units by a simple random method. Then, through the SIB system, the list of nulliparous pregnant women will be determined and will call with them, and among them who have inclusion  criteria and willing to participate in the study will be determined as the final list. Then people will be classified into two intervention groups and one control group (A or B or C) based on the random numbers table, Blinding description: For blinding, the pharmacist is asked to identify the medicine and placebo with the A_B_C group and the prescription in each package will be placed. So that the researcher does not know about the content of packages (medicine or placebo). The medicine is also given to participants as A or B or C, and participants will not be informed of the content of packages (medicine or placebo).
This blinding will also be available for the analyzer, and after finishing the statistical analysis the content of packages (medicine or placebo) will be asked from pharmacists.
At first, participants are justified about the study, and informed consent will be taken, but they are unaware of the content of packages (medicine or placebo). 
The clinical caregiver is also unaware of which A_B_C group contains each  medicine. The researcher re-evaluated the 35-week pregnant mothers who have inclusion criteria and at 37 weeks for obtaining castor oil referred them to the distributor of Gelax packages, who were unaware of the contents of the A-B-C packages and according to random number table, one of the ABC groups is assigned to each participant.
Another subcontractor is following up on the medical use plan of participants, and after the delivery, the other coworker will write the items research variables on the checklist based on the contents of the delivery file medical history. After completing the statistical analysis, the content of packages (medicine or placebo) will be asked from pharmacists.</study_design>
      <phase>3</phase>
      <hc_freetext>Bishop's score, Maternal and Neonatal outcomes.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group of use  Six Gelax capsules contains one gram or one thousand milligrams of castor oil, made by Barich Essence Company, which they consume from noon to noon ant starts from 38   weeks to delivery time. If a person forgets to consume for two days, it will be removed from the study.The reason for using Gelax instead of castor oil is its better taste, which is better for eating. Intervention 2: The second intervention group of use three Gelax capsules contains one gram or one thousand milligrams of castor oil, made by Barich Essence Company, which they consume from noon to noon ant starts from 38   weeks to delivery time. If a person forgets to consume for two days, it will be removed from the study.The reason for using Gelax instead of castor oil is its better taste, which is better for eating. Intervention 3: The control group of use three Gelax capsules contains one gram or one thousand milligrams of sunflower oil, made by Barich Essence Company, which they consume from noon to noon ant starts from 38 weeks to   delivery time. If a person forgets to consume for two days, it will be removed from the study.The reason for using Gelax instead of castor oil is its better taste, which is better for eating.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is Confidentiality of information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Azam Fatehzadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>6th Alley, Keshavarz Ave, Bahraman</address>
        <city>Rafsanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5967377441</zip>
        <telephone>+98 34 3425 5897</telephone>
        <email>azamfateh65@gmail.com</email>
        <affiliation>Rafsanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Zahra Saghafi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nursing and midwifery school, Sahely Blvd, Motahari Street</address>
        <city>Rafsanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7718796755</zip>
        <telephone>+98 34 3425 5900</telephone>
        <email>saghafiz@yahoo.com</email>
        <affiliation>Rafsanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Inform consent for participant in the study
Willingness to normal vaginal  delivery
Selection of Niknafs Maternity Center of Rafsanjan as the place of delivery
Mother age between 18-35 years
Pregnancy age: 38 weeks based on reliable first-trimester ultrasound or last menstrual period
Single-fetal with a cephalic presentation based on the latest ultrasound results</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Contraindications of Gelax
Sensitivity to Gelax capsules
Known history of psychological illness
Delivery complications such as polyhydramnios, oligohydramnios, preeclampsia, eclampsia, vaginal bleeding
History of having confirmed phsycological disorders
Having  any psychological disorders in the time of participation
Having epilepsy</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group of use  Six Gelax capsules contains one gram or one thousand milligrams of castor oil, made by Barich Essence Company, which they consume from noon to noon ant starts from 38   weeks to delivery time. If a person forgets to consume for two days, it will be removed from the study.The reason for using Gelax instead of castor oil is its better taste, which is better for eating.</i_keyword>
      <i_keyword>The second intervention group of use three Gelax capsules contains one gram or one thousand milligrams of castor oil, made by Barich Essence Company, which they consume from noon to noon ant starts from 38   weeks to delivery time. If a person forgets to consume for two days, it will be removed from the study.The reason for using Gelax instead of castor oil is its better taste, which is better for eating.</i_keyword>
      <i_keyword>The control group of use three Gelax capsules contains one gram or one thousand milligrams of sunflower oil, made by Barich Essence Company, which they consume from noon to noon ant starts from 38 weeks to   delivery time. If a person forgets to consume for two days, it will be removed from the study.The reason for using Gelax instead of castor oil is its better taste, which is better for eating.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Mean Bishop score. Timepoint: It will be measured in active phase of delivery time. Method of measurement: Bishop score is obtained by scoring the five criteria of dilatation, effacement, fetal head station, softness, and cervical position during  vaginal examination. Accordingly, each of the first three criteria is given a score of 0-3 and each of the following two criteria is given a score of 0-2.</prim_outcome>
      <prim_outcome>The frequency of spontaneous onset of labor. Timepoint: Time of delivery. Method of measurement: Check list.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Comparomisation the frequency of spontaneous  labor onset. Timepoint: Delivery duration. Method of measurement: Using checklist.</sec_outcome>
      <sec_outcome>The duration of the first stage of labor. Timepoint: From the onset of the active phase of labor to the complete opening of the cervix. Method of measurement: Checklist.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Rafsanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-06-17</approval_date>
        <contact_name>Ethics committee of Rafsanjan University of Medical Sciences</contact_name>
        <contact_address>Emam Ali Blvd, Rafsanjan Rafsanjan Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
